Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinomaARTICLE

European Journal of Clinical Investigation

Volumn 40, Issue 4, 2010, Pages 310-318

  Ho, Chih Ming ^a,b,c,f   Lai, Hung Cheng ^d   Huang, Shih Hung ^a   Chien, Tsai Yen ^a   Lin, Ming Chieh ^c,e   Chang, Shwu Fen ^c  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

MS PCR; Ovarian clear cell adenocarcinoma; Promoter methylation

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; RETINOBLASTOMA PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 3; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; SURVIVIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLEAR CELL CARCINOMA; COLON POLYPOSIS; CONTROLLED STUDY; CYST; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; DNA METHYLATION; EYE PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77949744412     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02266.x     Document Type: Article

References (26)

1. Serov SF, Scully RE, Robin IH. International Histological Classification of Tumors: No. 9. Histological Typing of Ovarian Tumours. Geneva : World Health Organization 1973. p. 37 42.
2. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989 32 : 342 349.
3. Ho CM, Huang YJ, Chen TC, Hung SH, Liu FS, Chien C-C et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004 94 : 197 203.
4. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histological type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000 88 : 2584 2589.
5. Ho CM, Chien TY, Shih BY, Huang SH. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003 88 : 394 399.
6. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003 163 : 2503 2512.
7. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999 85 : 669 677.
8. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005 104 : 1924 1930.
9. Okada S, Tsuda H, Takarabe T, Yoshikawa H, Taketani Y, Hirohashi S. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn J Cancer Res 2002 93 : 798 806.
10. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000 24 : 132 138.
11. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002 21 : 5427 5440.
12. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003 3 : 253 266.
13. Bovolenta P, Rodriguez J, Esteve P. Frizzled/RYK mediated signaling in axon guidance. Development 2006 133 : 4399 4408.
14. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004 95 : 741 744.
15. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007 13 : 4740 4749.
16. Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005 11 : 2123 2131.
17. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 2009 124 : 387 393.
18. Ho CM, Lin MC, Huang SH, Huang CJ, Lai HC, Chien TY et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009 112 : 307 313.
19. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 2001 19 : 537 542.
20. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004 64 : 6476 6481.
21. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001 61 : 8247 8255.
22. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K et al. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003 88 : S16 21.
23. Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World Gastroenterol 2006 28 : 7113 7117.
24. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004 64 : 883 888.
25. Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006 107 : 579 590.
26. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression marker of papillary bladder cancer. Lab Invest 2004 84 : 465 478.